Expected_老虎社区_美港股上老虎

2022-01-21

Expected

Why BioNTech, Moderna, Novavax, and Ocugen Stocks Are Plunging This Week<blockquote>为什么 BioNTech、Moderna、Novavax 和 Ocugen 股票本周暴跌</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":630113230,"tweetId":"630113230","gmtCreate":1642736174335,"gmtModify":1642736174599,"author":{"id":3582712430239719,"idStr":"3582712430239719","authorId":3582712430239719,"authorIdStr":"3582712430239719","name":"S071","avatar":"https://static.tigerbbs.com/1f21cc4747e7e36aaf24e423fd9d808b","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":19,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body>Expected</body></html>","htmlText":"<html><head></head><body>Expected</body></html>","text":"Expected","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/630113230","repostId":1100606079,"repostType":4,"repost":{"id":"1100606079","kind":"news","pubTimestamp":1642731768,"share":"https://www.laohu8.com/m/news/1100606079?lang=zh_CN&edition=full","pubTime":"2022-01-21 10:22","market":"us","language":"en","title":"Why BioNTech, Moderna, Novavax, and Ocugen Stocks Are Plunging This Week<blockquote>为什么 BioNTech、Moderna、Novavax 和 Ocugen 股票本周暴跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1100606079","media":"Motley Fool","summary":"What happenedShares of several COVID-19 vaccine makers are plunging this week.BioNTech(NASDAQ:BNTX)s","content":"<html><head></head><body>What happened<blockquote><html><head></head><body>发生了什么事</body></html></blockquote>Shares of several COVID-19 vaccine makers are plunging this week.BioNTech(NASDAQ:BNTX)stock is taking the worst drubbing, down 19.7% as of the market close on Thursday.Moderna&#39;s(NASDAQ:MRNA)shares were sinking 17.2%.Novavax(NASDAQ:NVAX) and Ocugen(NASDAQ:OCGN)stocks were falling 18.5% and 16.2%, respectively. All of these declines are based on data fromS&amp;P Global Market Intelligence.<blockquote>几家 COVID-19 疫苗制造商的股价本周暴跌。生物技术（纳斯达克股票代码：BNTX）股价遭受最严重的打击，截至周四收盘下跌 19.7%。现代s（纳斯达克股票代码：MRNA）股价下跌 17.2%。诺瓦瓦克斯（纳斯达克股票代码：NVAX）和奥库根（纳斯达克股票代码：OCGN）股价分别下跌 18.5% 和 16.2%。所有这些下降都是基于标准普尔全球市场情报公司的数据。</blockquote>There are multiple factors behind the sharp sell-off of these vaccine stocks. Perhaps most importantly, investors appear to be looking beyond the current surge in COVID-19 cases to a future where the demand for vaccines could be lower. The World Health Organization&#39;s (WHO) chief scientist also stated publicly on Tuesday that there&#39;s no evidence that booster doses are needed for healthy children and adolescents.<blockquote>这些疫苗股大幅抛售背后有多重因素。也许最重要的是，投资者似乎正在超越当前新冠肺炎病例的激增，展望未来对疫苗的需求可能会更低。世界卫生组织（世卫组织）首席科学家周二也公开表示，没有证据表明健康的儿童和青少年需要加强剂量。</blockquote><img src=\"https://static.tigerbbs.com/3d26561931e10f5ca9eea3a42da88654\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"/>IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote>BioNTech&#39;s shares are down the most because of new results announced this week from a clinical study conducted in Israel. This study found that a fourth booster dose of Comirnaty, the COVID-19 vaccine developed by BioNTech and its partner,Pfizer(NYSE:PFE), isn&#39;t effective at preventing infections by the coronavirus omicron variant.<blockquote>由于本周在以色列进行的一项临床研究公布了新结果，BioNTech 的股价跌幅最大。这项研究发现，BioNTech及其合作伙伴研发的新冠疫苗Comirnaty的第四剂加强剂，辉瑞（纽约证券交易所股票代码：PFE），在预防冠状病毒奥密克戎变种感染方面无效。</blockquote>This news also appeared to negatively affect Moderna. Like the Pfizer-BioNTech vaccine, Moderna&#39;s COVID-19 vaccine Spikevax uses messenger RNA (mRNA) technology. Investors seem to be concerned that a fourth booster dose of Spikevax won&#39;t be effective at preventing infection by omicron either.<blockquote>这一消息似乎也对 Moderna 产生了负面影响。与辉瑞-BioNTech疫苗一样，Moderna的COVID-19疫苗Spikevax使用信使RNA（mRNA）技术。投资者似乎担心第四剂 Spikevax 加强剂也无法有效预防奥密克戎病毒感染。</blockquote>So what<blockquote>那又怎样</blockquote>The prospects of reduced demand for COVID-19 vaccines is something that should be concerning to investors. This scenario would mean lower revenue for BioNTech and Moderna, which already have COVID-19 vaccines on the market in the U.S. and across the world.<blockquote>投资者应该关注新冠肺炎疫苗需求减少的前景。这种情况将意味着 BioNTech 和 Moderna 的收入下降，这两家公司已经在美国和世界各地的市场上销售了 COVID-19 疫苗。</blockquote>It could also translate to a tough climb ahead for Novavax and Ocugen. Novavax&#39;s COVID-19 vaccine has recently won authorizations or approvals in several countries, although not in the U.S. yet. Ocugen owns the rights to market Covaxin in the U.S. and Canada but hasn&#39;t secured authorizations in either country.<blockquote>这也可能意味着 Novavax 和 Ocugen 将面临艰难的攀登。Novavax 的 COVID-19 疫苗最近已在多个国家获得授权或批准，但尚未在美国获得批准。Ocugen 拥有在美国和加拿大销售科瓦克辛的权利，但尚未在这两个国家获得授权。</blockquote>However, it&#39;s too early to know if vaccine demand will actually decline significantly. The World Health Organization (WHO) warned this week that new coronavirus variants are likely to emerge after the current omicron wave wanes. The organization&#39;s COVID-19 technical lead, Maria Van Kerkhove, stated, &#34;We&#39;re hearing a lot of people suggest that omicron is the last variant, that it&#39;s over after this. And that is not the case because this virus is circulating at a very intense level around the world.&#34;<blockquote>然而，现在知道疫苗需求是否真的会大幅下降还为时过早。世界卫生组织（世卫组织）本周警告称，在当前的奥密克戎浪潮消退后，新的冠状病毒变种可能会出现。该组织的 COVID-19 技术负责人玛丽亚·范·科霍夫表示：“我们听到很多人认为奥密克戎是最后一个变种，在此之后就结束了。事实并非如此，因为这种病毒正在世界各地以非常激烈的速度传播。”</blockquote>As for the WHO&#39;s take that boosters for healthy children and adolescents aren&#39;t necessary, it remains to be seen if countries will go along. The U.S. government continues to encourage adolescents ages 12 and up to receive a third booster dose of the Pfizer-BioNTech vaccine.<blockquote>至于世卫组织认为健康儿童和青少年没有必要加强剂，各国是否会同意还有待观察。美国政府继续鼓励12岁及以上的青少年接种第三剂辉瑞-BioNTech疫苗加强针。</blockquote>But what about the new data from Israel about a fourth dose of Comirnaty? This probably isn&#39;t as worrisome as it might seem at first glance. Pfizer and BioNTech expect to have their omicron-specific vaccine ready by March. Moderna is developing a version of its vaccine that targets the omicron variant as well.<blockquote>但是来自以色列的关于第四剂Comirnaty的新数据呢？这可能并不像乍看起来那么令人担忧。辉瑞和BioNTech预计他们的奥密克戎特异性疫苗将在3月份准备就绪。Moderna正在开发一种针对奥密克戎变种的疫苗版本。</blockquote>Now what<blockquote>现在呢</blockquote>The most important thing, by far, for investors to watch now is what happens next with the COVID-19 pandemic. The spread of new coronavirus variants could completely change the market dynamics for these companies.<blockquote>到目前为止，投资者现在最需要关注的是 COVID-19 大流行接下来会发生什么。新型冠状病毒变种的传播可能会彻底改变这些公司的市场动态。</blockquote>Despite its dismal stock performance, Novavax has actually enjoyed some good news recently. The company won approvals for its COVID-19 vaccine in France and in Australia over the last several days. Novavax expects to soon complete its filing for Emergency Use Authorization (EUA) in the U.S.<blockquote>尽管股票表现惨淡，但Novavax最近实际上还是享受到了一些好消息。过去几天，该公司的 COVID-19 疫苗在法国和澳大利亚获得了批准。Novavax 预计很快将完成在美国的紧急使用授权 (EUA) 申请。</blockquote>Ocugen has already submitted for U.S. EUA of Covaxin in children. However, the company still awaits the lifting of a clinical hold placed by the U.S. Food and Drug Administration on a planned late-stage clinical study of the vaccine.<blockquote>Ocugen已经提交了美国儿童科瓦克辛EUA。然而，该公司仍在等待美国解除临床禁令。美国食品药品监督管理局关于计划中的疫苗后期临床研究。</blockquote></body></html><blockquote></blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why BioNTech, Moderna, Novavax, and Ocugen Stocks Are Plunging This Week<blockquote>为什么 BioNTech、Moderna、Novavax 和 Ocugen 股票本周暴跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy BioNTech, Moderna, Novavax, and Ocugen Stocks Are Plunging This Week<blockquote>为什么 BioNTech、Moderna、Novavax 和 Ocugen 股票本周暴跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2022-01-21 10:22\n\n</h4>\n</header>\n<article>\n<html><head></head><body>What happened<blockquote><html><head></head><body>发生了什么事</body></html></blockquote>Shares of several COVID-19 vaccine makers are plunging this week.BioNTech(NASDAQ:BNTX)stock is taking the worst drubbing, down 19.7% as of the market close on Thursday.Moderna&#39;s(NASDAQ:MRNA)shares were sinking 17.2%.Novavax(NASDAQ:NVAX) and Ocugen(NASDAQ:OCGN)stocks were falling 18.5% and 16.2%, respectively. All of these declines are based on data fromS&amp;P Global Market Intelligence.<blockquote>几家 COVID-19 疫苗制造商的股价本周暴跌。生物技术（纳斯达克股票代码：BNTX）股价遭受最严重的打击，截至周四收盘下跌 19.7%。现代s（纳斯达克股票代码：MRNA）股价下跌 17.2%。诺瓦瓦克斯（纳斯达克股票代码：NVAX）和奥库根（纳斯达克股票代码：OCGN）股价分别下跌 18.5% 和 16.2%。所有这些下降都是基于标准普尔全球市场情报公司的数据。</blockquote>There are multiple factors behind the sharp sell-off of these vaccine stocks. Perhaps most importantly, investors appear to be looking beyond the current surge in COVID-19 cases to a future where the demand for vaccines could be lower. The World Health Organization&#39;s (WHO) chief scientist also stated publicly on Tuesday that there&#39;s no evidence that booster doses are needed for healthy children and adolescents.<blockquote>这些疫苗股大幅抛售背后有多重因素。也许最重要的是，投资者似乎正在超越当前新冠肺炎病例的激增，展望未来对疫苗的需求可能会更低。世界卫生组织（世卫组织）首席科学家周二也公开表示，没有证据表明健康的儿童和青少年需要加强剂量。</blockquote><img src=\"https://static.tigerbbs.com/3d26561931e10f5ca9eea3a42da88654\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"/>IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote>BioNTech&#39;s shares are down the most because of new results announced this week from a clinical study conducted in Israel. This study found that a fourth booster dose of Comirnaty, the COVID-19 vaccine developed by BioNTech and its partner,Pfizer(NYSE:PFE), isn&#39;t effective at preventing infections by the coronavirus omicron variant.<blockquote>由于本周在以色列进行的一项临床研究公布了新结果，BioNTech 的股价跌幅最大。这项研究发现，BioNTech及其合作伙伴研发的新冠疫苗Comirnaty的第四剂加强剂，辉瑞（纽约证券交易所股票代码：PFE），在预防冠状病毒奥密克戎变种感染方面无效。</blockquote>This news also appeared to negatively affect Moderna. Like the Pfizer-BioNTech vaccine, Moderna&#39;s COVID-19 vaccine Spikevax uses messenger RNA (mRNA) technology. Investors seem to be concerned that a fourth booster dose of Spikevax won&#39;t be effective at preventing infection by omicron either.<blockquote>这一消息似乎也对 Moderna 产生了负面影响。与辉瑞-BioNTech疫苗一样，Moderna的COVID-19疫苗Spikevax使用信使RNA（mRNA）技术。投资者似乎担心第四剂 Spikevax 加强剂也无法有效预防奥密克戎病毒感染。</blockquote>So what<blockquote>那又怎样</blockquote>The prospects of reduced demand for COVID-19 vaccines is something that should be concerning to investors. This scenario would mean lower revenue for BioNTech and Moderna, which already have COVID-19 vaccines on the market in the U.S. and across the world.<blockquote>投资者应该关注新冠肺炎疫苗需求减少的前景。这种情况将意味着 BioNTech 和 Moderna 的收入下降，这两家公司已经在美国和世界各地的市场上销售了 COVID-19 疫苗。</blockquote>It could also translate to a tough climb ahead for Novavax and Ocugen. Novavax&#39;s COVID-19 vaccine has recently won authorizations or approvals in several countries, although not in the U.S. yet. Ocugen owns the rights to market Covaxin in the U.S. and Canada but hasn&#39;t secured authorizations in either country.<blockquote>这也可能意味着 Novavax 和 Ocugen 将面临艰难的攀登。Novavax 的 COVID-19 疫苗最近已在多个国家获得授权或批准，但尚未在美国获得批准。Ocugen 拥有在美国和加拿大销售科瓦克辛的权利，但尚未在这两个国家获得授权。</blockquote>However, it&#39;s too early to know if vaccine demand will actually decline significantly. The World Health Organization (WHO) warned this week that new coronavirus variants are likely to emerge after the current omicron wave wanes. The organization&#39;s COVID-19 technical lead, Maria Van Kerkhove, stated, &#34;We&#39;re hearing a lot of people suggest that omicron is the last variant, that it&#39;s over after this. And that is not the case because this virus is circulating at a very intense level around the world.&#34;<blockquote>然而，现在知道疫苗需求是否真的会大幅下降还为时过早。世界卫生组织（世卫组织）本周警告称，在当前的奥密克戎浪潮消退后，新的冠状病毒变种可能会出现。该组织的 COVID-19 技术负责人玛丽亚·范·科霍夫表示：“我们听到很多人认为奥密克戎是最后一个变种，在此之后就结束了。事实并非如此，因为这种病毒正在世界各地以非常激烈的速度传播。”</blockquote>As for the WHO&#39;s take that boosters for healthy children and adolescents aren&#39;t necessary, it remains to be seen if countries will go along. The U.S. government continues to encourage adolescents ages 12 and up to receive a third booster dose of the Pfizer-BioNTech vaccine.<blockquote>至于世卫组织认为健康儿童和青少年没有必要加强剂，各国是否会同意还有待观察。美国政府继续鼓励12岁及以上的青少年接种第三剂辉瑞-BioNTech疫苗加强针。</blockquote>But what about the new data from Israel about a fourth dose of Comirnaty? This probably isn&#39;t as worrisome as it might seem at first glance. Pfizer and BioNTech expect to have their omicron-specific vaccine ready by March. Moderna is developing a version of its vaccine that targets the omicron variant as well.<blockquote>但是来自以色列的关于第四剂Comirnaty的新数据呢？这可能并不像乍看起来那么令人担忧。辉瑞和BioNTech预计他们的奥密克戎特异性疫苗将在3月份准备就绪。Moderna正在开发一种针对奥密克戎变种的疫苗版本。</blockquote>Now what<blockquote>现在呢</blockquote>The most important thing, by far, for investors to watch now is what happens next with the COVID-19 pandemic. The spread of new coronavirus variants could completely change the market dynamics for these companies.<blockquote>到目前为止，投资者现在最需要关注的是 COVID-19 大流行接下来会发生什么。新型冠状病毒变种的传播可能会彻底改变这些公司的市场动态。</blockquote>Despite its dismal stock performance, Novavax has actually enjoyed some good news recently. The company won approvals for its COVID-19 vaccine in France and in Australia over the last several days. Novavax expects to soon complete its filing for Emergency Use Authorization (EUA) in the U.S.<blockquote>尽管股票表现惨淡，但Novavax最近实际上还是享受到了一些好消息。过去几天，该公司的 COVID-19 疫苗在法国和澳大利亚获得了批准。Novavax 预计很快将完成在美国的紧急使用授权 (EUA) 申请。</blockquote>Ocugen has already submitted for U.S. EUA of Covaxin in children. However, the company still awaits the lifting of a clinical hold placed by the U.S. Food and Drug Administration on a planned late-stage clinical study of the vaccine.<blockquote>Ocugen已经提交了美国儿童科瓦克辛EUA。然而，该公司仍在等待美国解除临床禁令。美国食品药品监督管理局关于计划中的疫苗后期临床研究。</blockquote></body></html><blockquote></blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2022/01/20/why-biontech-moderna-novavax-and-ocugen-stocks-are/\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","OCGN":"Ocugen","NVAX":"诺瓦瓦克斯医药","MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2022/01/20/why-biontech-moderna-novavax-and-ocugen-stocks-are/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1100606079","content_text":"What happenedShares of several COVID-19 vaccine makers are plunging this week.BioNTech(NASDAQ:BNTX)stock is taking the worst drubbing, down 19.7% as of the market close on Thursday.Moderna's(NASDAQ:MRNA)shares were sinking 17.2%.Novavax(NASDAQ:NVAX) and Ocugen(NASDAQ:OCGN)stocks were falling 18.5% and 16.2%, respectively. All of these declines are based on data fromS&P Global Market Intelligence.There are multiple factors behind the sharp sell-off of these vaccine stocks. Perhaps most importantly, investors appear to be looking beyond the current surge in COVID-19 cases to a future where the demand for vaccines could be lower. The World Health Organization's (WHO) chief scientist also stated publicly on Tuesday that there's no evidence that booster doses are needed for healthy children and adolescents.IMAGE SOURCE: GETTY IMAGES.BioNTech's shares are down the most because of new results announced this week from a clinical study conducted in Israel. This study found that a fourth booster dose of Comirnaty, the COVID-19 vaccine developed by BioNTech and its partner,Pfizer(NYSE:PFE), isn't effective at preventing infections by the coronavirus omicron variant.This news also appeared to negatively affect Moderna. Like the Pfizer-BioNTech vaccine, Moderna's COVID-19 vaccine Spikevax uses messenger RNA (mRNA) technology. Investors seem to be concerned that a fourth booster dose of Spikevax won't be effective at preventing infection by omicron either.So whatThe prospects of reduced demand for COVID-19 vaccines is something that should be concerning to investors. This scenario would mean lower revenue for BioNTech and Moderna, which already have COVID-19 vaccines on the market in the U.S. and across the world.It could also translate to a tough climb ahead for Novavax and Ocugen. Novavax's COVID-19 vaccine has recently won authorizations or approvals in several countries, although not in the U.S. yet. Ocugen owns the rights to market Covaxin in the U.S. and Canada but hasn't secured authorizations in either country.However, it's too early to know if vaccine demand will actually decline significantly. The World Health Organization (WHO) warned this week that new coronavirus variants are likely to emerge after the current omicron wave wanes. The organization's COVID-19 technical lead, Maria Van Kerkhove, stated, \"We're hearing a lot of people suggest that omicron is the last variant, that it's over after this. And that is not the case because this virus is circulating at a very intense level around the world.\"As for the WHO's take that boosters for healthy children and adolescents aren't necessary, it remains to be seen if countries will go along. The U.S. government continues to encourage adolescents ages 12 and up to receive a third booster dose of the Pfizer-BioNTech vaccine.But what about the new data from Israel about a fourth dose of Comirnaty? This probably isn't as worrisome as it might seem at first glance. Pfizer and BioNTech expect to have their omicron-specific vaccine ready by March. Moderna is developing a version of its vaccine that targets the omicron variant as well.Now whatThe most important thing, by far, for investors to watch now is what happens next with the COVID-19 pandemic. The spread of new coronavirus variants could completely change the market dynamics for these companies.Despite its dismal stock performance, Novavax has actually enjoyed some good news recently. The company won approvals for its COVID-19 vaccine in France and in Australia over the last several days. Novavax expects to soon complete its filing for Emergency Use Authorization (EUA) in the U.S.Ocugen has already submitted for U.S. EUA of Covaxin in children. However, the company still awaits the lifting of a clinical hold placed by the U.S. Food and Drug Administration on a planned late-stage clinical study of the vaccine.","news_type":1,"symbols_score_info":{"BNTX":0.9,"MRNA":0.9,"NVAX":0.9,"OCGN":0.9}},"isVote":1,"tweetType":1,"viewCount":1142,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":8,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/630113230"}